HMLSF - Horizons Marijuana Life Sciences Index ETF

Other OTC - Other OTC Delayed Price. Currency in USD
7.35
+0.01 (+0.20%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close7.33
Open7.26
BidN/A x N/A
AskN/A x N/A
Day's Range7.25 - 7.47
52 Week Range6.10 - 18.00
Volume47,128
Avg. VolumeN/A
Net AssetsN/A
NAVN/A
PE Ratio (TTM)N/A
YieldN/A
YTD Daily Total ReturnN/A
Beta (5Y Monthly)N/A
Expense Ratio (net)N/A
Inception DateN/A
  • Benzinga

    House Committee Holds Hearing On 'Cannabis Policies for the New Decade'

    Two of these - the Marijuana Freedom and Opportunity Act and the Marijuana Opportunity Reinvestment and Expungement (MORE) Act - involve federal descheduling of cannabis from the Controlled Substances Act. The latter has already received approval from the House Judiciary Committee.

  • Benzinga

    A Snapshot Of America's Medical Marijuana Markets: Ohio

    Ohio Gov. John Kasich signed House Bill 523 into law in June 2016, legalizing medical cannabis in the state. The Buckeye State has run into problems such as patient dissatisfaction in the first year of the state's medical marijuana program, and the state has declined to add conditions such as anxiety and autism to the list of qualifying conditions. End-of-year data from the state Medical Marijuana Control Program revealed that $58.3 million in product sales had been made as of Jan. 6 across the state's 46 operating dispensaries.

  • Cannabis stocks led lower by Aurora and Hexo
    MarketWatch

    Cannabis stocks led lower by Aurora and Hexo

    Hexo Corp. and Aurora Cannabis Inc., shares lead weed stocks mostly lower Monday, adding to what is shaping up to be a third straight day of losses in 2020.

  • Aphria Stock Has Work to Do to Maintain the Trust of Investors
    InvestorPlace

    Aphria Stock Has Work to Do to Maintain the Trust of Investors

    Cannabis investors are hoping that 2020 will bring more clarity to marijuana stocks. After rising to record high levels in 2018, cannabis stock prices went down in a puff of smoke. One of the primary problems for cannabis stocks was a lack of profitability. Investors saw that making marijuana legal was only part of the battle. Canadian regulators have been slow to approve retail store licenses, creating a supply-demand imbalance.Source: Shutterstock With that said, Aphria (NYSE:APHA) stock has stood out for good reasons. Aphria has shown a profit where other cannabis stocks have failed. In 2019, APHA stock price fell "only" 17%. In context, the Horizons Marijuana Life Sciences ETF (OTCMKTS:HMLSF) dropped 39% for the year.The question that many investors have is whether or not Aphria can generate actual sales that will help justify the company's 2020 price targets.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Balance Sheet Sheds Suspicion on Those Positive EarningsAphria has turned a profit in its last two quarters. However, a closer look at the company's balance sheet shows that the profit was due to a surge in non-operating income. The problem with non-operating income is that it can be a fickle beast. And without the non-operating income, Aphria would not be profitable. * 7 Stocks to Buy for January and Beyond Another problem for Aphria is the way they estimate the value of their crops on a quarterly basis. Additionally, APHA must estimate the projected cost to sell those goods. The result is a positive fair-value adjustment that doesn't reflect how well (or in this case poorly) the actual performance of the company's business was. Mark Hake took a much closer look at Aphria's balance sheet and came to a bearish conclusion.Now to be fair, this is not an issue that is unique to Aphria. The International Financial Reporting Standards for Canadian stocks sets the standard. However, the takeaway is that Aphria would not be profitable on an operating basis if those costs are stripped away. Will APHA Be a Victim of Its Own Forecasts?The other problem for APHA is that they have forecasted strong earnings. In its most recent earnings call, Aphria said it was expecting net revenue for fiscal 2020 of between 650 million CAD and 750 million CAD. The quarter that ended was Aphria's first quarter of the 2020 fiscal year. With net revenue of approximately 126 million CAD, the company was less than 20% towards the low end of that forecast.So, what do analysts project for the current quarter? The good news is that the consensus estimate is for revenue of 130 million CAD. The bad news is that number is well short of the 200 million CAD that Aphria needs to put them at about the halfway mark of the low end of its forecast. Aphria Does Not Need Any More Poor HeadlinesAphria drew the ire of investors due to allegations of wrongdoing in how it acquired Latin American assets. As I wrote back in October, an independent committee (formed by Aphria's board) found many of the allegations to be untrue. But the resulting conflicts of interest led to the resignation of former CEO Vic Neufeld.If this was the company's first offense it would be damaging. However, with it being a second offense, the company is skating on thin ice. Aphria is going to have a hard time meeting the revenue expectations that it has set. What Should Investors Do with Aphria Stock?Whenever I see a stock with the potential for a range of outcomes, I have to call it a hold. And that's what I see with Aphria. The cannabis industry should have a better 2020 simply because most of the frothiness has been wrung out of the stocks. But as investors begin to look at these stocks based on their merits, what will they see?In the case of Aphria, they have bought some time due to perfectly legal but unsustainable accounting measures. The company has yet to show the cash burn of its competitors. But it has already taken a 50 million CAD write-down on the previously mentioned Latin American transactions. And that is confirming the suspicion that Aphria overpaid for those assets. This means more write-downs, and share dilution, is likely.All things considered, 2020 is the year many cannabis companies must begin to prove their case to investors. Until they do, investors can hit the pause button on Aphria.As of this writing, Chris Markoch did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for January and Beyond * 7 Excellent Value Stocks to Buy for 2020 * 5 Hot Housing Stocks That Could Stay Hot in 2020 The post Aphria Stock Has Work to Do to Maintain the Trust of Investors appeared first on InvestorPlace.

  • Weed stocks rally on last day of a brutal year
    MarketWatch

    Weed stocks rally on last day of a brutal year

    After a brutal year for cannabis investors, weed stocks rebounded in the final trading session of the decade.

  • Benzinga

    NatGeo's Jason Silva On Cannabis, Psychology And 'The Psychedelic Renaissance'

    Jason Silva is a TV personality, filmmaker, speaker and futurist. Silva comes from a culturally driven household in Venezuela, where he lived until he moved to the U.S. at 18. As a teenager, Silva says he became aware that the environment in which cannabis is consumed is as important as the quality of the plant itself.

  • Aurora Cannabis stock slammed by executive departure and insiders selling
    MarketWatch

    Aurora Cannabis stock slammed by executive departure and insiders selling

    Aurora Cannabis Inc. shares slid 8% Monday, after the company announced the exit of a key executive amid reports of insider selling, dilutive financing moves and questions about the company’s path to profitability.

  • Benzinga

    Data: Cannabis M&A And Raises Tanking Hard As 2020 Approaches

    The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and intelligence they need to make informed decisions regarding deal valuations, terms, and structures. Since its inception, the Viridian Cannabis Deal Tracker has tracked and analyzed more than 2,400 capital raises totaling over $29 billion as well as more than 900 M&A transactions.

  • Benzinga

    Here's How To Showcase Your Cannabis Company At SXSW – For Free!

    Among the many hot cannabis panels and events we’ll see at SXSW 2020, there’s one offering you an opportunity to showcase your cannabis company for free: Cannabis Jumpstart: A Business Showcase, hosted by CanopyBoulder. The event will consist of six cannabis, hemp or CBD companies presenting their businesses live, on stage, in front of a panel of cannabis experts and venture capitalists. The best presentation as determined by the judges will be announced at the end of the session and the winner will receive a free pass to SXSW 2021, along with a basket of other prizes.

  • Benzinga

    The Week In Cannabis: Peru Rolls Out Sales, Uruguay Updates Rules, MLB Stops Testing Players, Canopy Hires New CEO

    Only a week after Brazil came out with medical cannabis regulations , another Latin American nation has taken a step forward in the marijuana space. Peru  finally rolled out the sale of medical cannabis ...

  • Benzinga

    Viridian Cannabis Deal Tracker: Investment And M&A Remain Very Low, Compared To 2018

    The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and intelligence they need to make informed decisions regarding deal valuations, terms, and structures. Since its inception, the Viridian Cannabis Deal Tracker has tracked and analyzed more than 2,400 capital raises totaling over $29 billion as well as more than 900 M&A transactions.

  • Benzinga

    Exclusive: WAYV, Hypur Partner To Launch Digital, 'Credit Card-Like' Finance Solution For Cannabis Industry

    WAYV, the VC-backed company launched by Eaze’s founder Keith McCarty, and finance and compliance tech company Hypur have partnered up to launch a “credit card-like” B2B technology solution for the cannabis industry. The payments solution, aimed at the entire cannabis supply chain, helps businesses reduce their reliance on cash, move money across the supply chain digitally, and automate compliance and taxes. McCarty told Benzinga WAYV was founded to solve one the biggest problems the legal cannabis industry faces today: finances.

  • Benzinga

    Uruguay Senate Approves New Bill To Regulate Access To Medical Cannabis

    To help put a definitive end to persisting illicit cannabis markets, Uruguay's senate has passed a new bill to regulate medical marijuana. The bill, "A Comprehensive Law for the Promotion and Access to Medical and Therapeutic Cannabis," was introduced into Congress by the "Ir" sector of the “Frente Amplio” party, and approved unanimously. The new bill also presents guidelines for pharmaceutical compounding.

  • Benzinga

    Podcast: Hip Hop And The Politics Of Weed With Benzinga's Javier Hasse And Digital Underground's 'Vegas Don'

    This week on the show, we dive into hot topic in the world of Hip Hop and Politics. Javier Hasse is the author of the book Start Your Own Cannabis Business (Entrepreneur Press 2018), which hit the #1 Best Seller spot on Amazon, as well as a cannabis-focused, award-winning reporter and editor, with more than 4,700 unique articles published across numerous mass media outlets.

  • Benzinga

    Benzinga Heads To Miami For The First Cannabis Capital Conference Of 2020

    DETROIT — The premier gathering of cannabis entrepreneurs and investors in North America, the Benzinga Cannabis Capital Conference , is heading to Miami in 2020 for its sixth installment. The conference, ...

  • Benzinga

    Federal Agencies Clarify Banking Rules For Hemp Businesses

    On Oct. 29, the United States Department of Agriculture released its long-awaited draft regulations for hemp production. Although hemp had been officially descheduled from the Controlled Substances Act by the 2018 Farm Bill, farmers and producers were still waiting on the guidance. The crop was federally legalized in 2014, and the 2018 Bill extended a program for domestic hemp production.

  • Benzinga

    The Global Alliance For Cannabis Commerce Launches Voluntary Private Industry Standard

    The Global Alliance for Cannabis Commerce said Thursday it's starting a nationwide, voluntary industry certification that vouches for safety and purity in cannabis product testing. The program should provide the consumers and licensed sellers with the certainty of the purity and safety of the legal product, under raised state standards. The Global Alliance for Cannabis Commerce will open nominations for membership on the Standards Committee on Thursday, and end it on Jan. 30, 2020.

  • Benzinga

    Brazil Regulates Sale Of Medical Marijuana Products

    Brazil has become the third Latin American country to regulate the sale of medical marijuana after Uruguay and Colombia. On Tuesday, ANVISA (the National Agency for Health Supervision) announced it has unanimously approved the regulation of medical marijuana to be sold at pharmacies and drugstores nationwide. Brazil is Latin America’s biggest and most-populated country, with over 210 million inhabitants.

  • Benzinga

    A Snapshot Of America's Medical Marijuana Markets: Maryland

    Like many states, Maryland has a medical cannabis market that shows growth, potential and significant pain points. Maryland began revising its cannabis laws in 2012 when state lawmakers approved a medical marketplace. In 2017, Maryland's medical program became operational.

  • Cannabis stocks boosted by expectations of a spike in spending on weed over holiday weekend
    MarketWatch

    Cannabis stocks boosted by expectations of a spike in spending on weed over holiday weekend

    Cannabis stocks rose Wednesday to recover some of their prior-day losses, boosted by expectations for a steep rise in spending on cannabis over the Thanksgiving period, one of the busier shopping periods of the year.

  • Benzinga

    A Look At The Best Paying Jobs In Cannabis And Other Hiring Trends

    Last week, Vangst released its 2019 Salary Guide, a complete overview of the growth of the cannabis industry over the past year. The report includes a guide to hiring competitively in the industry, a map of legalization, and hiring trends. The cannabis industry is in a phase of constant growth and companies are forced to invariably hire new people.

  • Benzinga

    Cannabis Consumer Profiles, Popular Brands And More: Exclusive Insights From The Newest AI Data Platform For The Industry

    This week, Ceylon Solutions, a cannabis-centered software development company, and data analytics firm Zefyr, launched Zefyr Dazh, an artificial intelligence data analytics platform for the cannabis industry. While there is plenty of data in the cannabis industry today, the company says much of it is disparate and misinterpreted by users. “Much of the data on Zefyr Dazh is updated in real-time and has an 85% assurance rate, which is unheard of in the cannabis industry," Marion Mariathasan,founder and Chairman of Ceylon Solutions, told Benzinga.

  • Benzinga

    Tax Considerations For Cannabis Business And Investment

    The growing cannabis industry has piqued the interest of many business owners and investors who predict it could become a multi-billion dollar industry. Legal developments bolster this enthusiasm, as more than 30 states and the District of Columbia have thus far legalized marijuana for medical and/or recreational purposes.

  • Cannabis stocks are a sea of red as selloff stretches to sixth straight day
    MarketWatch

    Cannabis stocks are a sea of red as selloff stretches to sixth straight day

    Cannabis stocks were a sea of red again on Monday, with Aurora Cannabis tumbling another 7% following disappointing earnings and MedMen down 17% on news of job cuts and asset sales.

  • Benzinga

    Cannabis Industry Reacts To Biden's 'Gateway Drug' Remark: 'Prohibition Is The Real Gateway'

    On Saturday, former vice president and Democratic presidential candidate Joe Biden came out against federal legalization of cannabis. "The truth of the matter is, there's not nearly been enough evidence that has been acquired as to whether or not it is a gateway drug," said Biden, who added that more research needs to be done before he would sign off on federal legalization. In his 36-year-long career as a U.S. Senator, Biden stood behind a number of bills that supported tough punishment for non-violent possession charges.